Human Mucosal Immunization 2025 held in Shenzhen, focusing on the frontier challenges of bacterial infection and immune protection mechanisms

18 07, 2025

From July 4 to 6, the Human Mucosal Immunization 2025: Bacterial Infections and Beyond Challenges in Defining Correlates of Protection was successfully held in Shenzhen, China. This international conference was supported by the ANSO Collaborative Research Project (ANSO-CR-KP-2022-01) and hosted by the Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences (hereinafter referred to as "SIAT"). The conference brought together well-known immunologists and microbiologists from China, Italy, Sweden, Brazil, South Korea, the United Kingdom and other countries, as well as vaccine research and development project leaders from internationally renowned biopharmaceutical companies including CanSino and Fennogene, to conduct in-depth discussions on core topics such as mucosal immune protection mechanisms, bacterial infection prevention and control strategies, and vaccine development, aiming to promote interdisciplinary cooperation and technological innovation in the field of global mucosal immunity.

Liang Dong, Vice President of SIAT, said, promoting international cooperation in mucosal immunity research is not only the key to responding to public health threats such as bacterial infections, but also the only way to achieve a human health community. He emphasized that mucosal immunity is the first line of defense for the human body to defend against pathogens, and its research is of great significance to vaccine development and disease prevention, and control.

Wang Zhuo, Program Officer from the ANSO Secretariat, delivered an introductory remark highlighting ANSO’s mission and key actions in fostering international scientific collaboration and sustainable development. She called for attention, engagements, and joint efforts on ANSO projects and events to enhance research and innovation capabilities and advance human health and well-being.

Aldo Tagliabue, Chief Scientist of the Inflammation and Vaccine Laboratory of SIAT, delivered a speech at the conference. He emphasized: “In response to the major challenges of global bacterial infection and mucosal immune protection mechanism research, it is crucial to cultivate scientists with both an international vision and cutting-edge technical capabilities. The conference is not only a platform for knowledge sharing, but also a valuable growth opportunity for researchers. ”

Rino Rappuoli, Scientific Director of Fondazione Biotecnopolo di Siena, introduced the overview of the foundation and shared the status of vaccine development in different countries and regions around the world. At the same time, he put forward valuable guidance on the development of various aspects of vaccine prevention and treatment.

Professor Diana Boraschi, Honorary Director of the Inflammation and Vaccine Laboratory, Shenzhen Institute of Advanced Medicine, and Academician of the Italian National Academy, presided over the meeting. She hoped that this conference would effectively promote in-depth dialogue among global researchers on the research of mucosal immune protection mechanisms and create more opportunities for cross-border scientific research cooperation.

During the event, exchanges and discussions were held with many vaccine company project leaders attending the meeting, highlighting the deep synergy between basic immunology research and clinical transformation, and promoting the application of mucosal immune mechanisms in the prevention and control of infectious diseases.